Click here to view this e-mail in a browser.
Conference Brief
OphthalmologyTimes.com

DAY 3 - Tuesday, May 7


GENERAL

One-third of diabetics fail to get eye exams

An estimated 25 million people in the United States have diabetes and face a higher risk for ophthalmic complications, including glaucoma, cataracts, and diabetic retinopathy. However, more than one-third of all persons in the United States with diabetes did not undergo an eye exam in the past year, said Fang Ko, MD. » MORE


BLOG FROM ARVO

Editor's blog: The feeding frenzy of science known as the Poster Sessions

One of the most unique aspects of the Association for Research in Vision and Ophthalmology (ARVO) meeting that ophthalmic clinicians won't find at any other meeting—including the American Academy of Ophthalmology (AAO) and American Society of Refractive and Cataract Surgery (ASCRS) meetings—is the poster sessions. » MORE


RETINA

Vitrectomy for floaters can be safe, effective

Symptomatic floaters can be treated safely and effectively with vitrectomy using 25-gauge instruments, and without inducing posterior vitreous detachment (PVD) or removing the anterior vitreous, said Christianne A. Wa, a third-year medical student at USC School of Medicine, Los Angeles. » MORE

Compound has potential in retinoblastoma

A new compound shows potential as a novel targeted therapy for retinoblastoma. While studies are still in the preliminary stages, the compound known as sd-rxRNA was able to penetrate all cell layers of the retina and was taken up by tumor cells within 24 hours of intravitreal administration, said Michael Byrne, PhD. » MORE

Faces detected with retinal prosthesis

New data show that a retinal prosthesis system is capable of providing face detection functionality to blind individuals, said Paulo E. Stanga, MD. » MORE


DISCLAIMER:
This information has been independently developed and provided by the editors of Ophthalmology Times. The sponsor does not endorse and is not responsible for the accuracy of the content or for practices or standards of non-sponsor sources.

Ophthalmology Times ‏@OphthTimes

Ranibizumab versus bevacizumab: Results Tuesday from the IVAN2 and GEFAL trials #ARVO2013 #ophthalmology

Ophthalmology Times ‏@OphthTimes

"Timing is Everything" and "Soaring Aspirations" for Monday's Proctor Medal Lecture and Weisenfeld Award Lecture #ARVO2013 #ophthalmology

Ophthalmology Times ‏@OphthTimes

Visit Ophthalmology Times in the exhibit hall at booth 1419 #ARVO2013 #ophthalmology


Top Tweets


We welcome your feedback!
Please send your comments to:

Mark L. Dlugoss

Editor-in-Chief

Advanstar Eye Health Group

mdlugoss@advanstar.com